We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Fluorescence-Based Photodynamic Product Detects Premalignant/Malignant Colorectal Cancer Lesions

By Labmedica staff writers
Posted on 28 May 2008
A new fluorescence-based photodynamic diagnostic (PDD) product has produced excellent results in a clinical trial evaluating its potential for detecting premalignant/malignant lesions in patients with suspected colorectal cancer.

A dose-finding phase I/II study of the new product, Lumacan, was performed at two hospitals in Germany using fluorescence diagnosis in 38 patients with suspected colorectal cancer. More...
Patients received local instillation of Lumacan in the colon before proceeding with standard colonoscopy using both white and blue (fluorescence) light. The light-sensitive active ingredient in Lumacan, hexalevulinate (HAL), is rapidly accumulated in metabolically active cancerous and precancerous cells, and it fluoresces red when illuminated with blue light.

The results of the study found that of the 91 lesions identified in 25 patients with suspected colorectal cancer using the gold standard approach of tissue histology, 90 lesions were detected using PDD examination with Lumacan, while only 55 lesions were detected using white-light endoscopy. The approach using Lumacan therefore identified 36 more polyps than with the standard clinical procedure of white-light endoscopic imaging, an improvement of approximately 65%. No systemic or local side effects related to the use of Lumacan were reported.

The principle investigator of the trial, Dr. Brigitte Mayinger from the Hospital Munich-Pasing, (Munich, Germany) said, "In this trial, Lumacan conclusively demonstrated its ability to induce specific and selective fluorescence in colorectal lesions thereby significantly increasing the lesion detection rate in patients with colorectal adenoma and early carcinoma compared with standard methods. This new photodynamic diagnosis technique can also detect the flat, nonvisible lesions and hidden polyps that are difficult to observe and which if missed can lead to recurrent or progressive disease.”

Lumacan (hexaminolevulinate) is being developed by Photocure (Oslo, Norway) to improve standard colonoscopy in patients with suspected colorectal cancer. This new product is based on the Hexvix product, which is already approved in Europe for the improved diagnosis of bladder and cancer lesions.

The final study results were presented at Digestive Disease Week (DDW) in San Diego (CA, USA) on May 21, 2008, by Dr. Mayinger.


Related Links:
Photocure

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.